OraSure Technologies, Inc. (NASDAQ:OSUR) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET

Company Participants

Kathleen Weber - President of Molecular Solutions

Lisa Nibauer - President of Diagnostics

Nancy Gagliano - Interim Chief Executive Officer & Director

Scott Gleason - Senior Vice President of Investor Relations & Corporate Communications and Interim Chief Financial Officer

Conference Call Participants

Casey Woodring - JPMorgan Chase

Andrew Cooper - Raymond James

Frank Takkinen - Lake Street Capital Markets

Operator

Good afternoon, ladies and gentlemen and welcome to the OraSure Technologies First Quarter Earnings Conference Call. [Operator Instructions] Later, we will conduct a question-and-answer session.

I'd now like to introduce your host, Scott Gleason. Mr. Gleason, you may now begin.

Scott Gleason

Thanks, Paul. Good afternoon and welcome to OraSure Technologies first quarter '22 earnings call. I'm Scott Gleason, the Interim CFO and SVP of Investor Relations and Communications. Presenting with me today for OraSure is Dr. Nancy Gagliano, our Interim President and Chief Executive Officer; Lisa Nibauer, our President of Diagnostics and Cathy Weber, our President of Molecular Solutions.

As a reminder, today's webcast is being recorded and the recording along with the slide presentation accompanying the webcast can be found on our Investor Relations website. Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share and other financial performance, product development performance, shipment and markets, business plans, regulatory filings and approvals, expectations and strategies. Actual results could be significantly different. Factors that could affect our results are discussed more fully in the company's SEC filings, including its registration statements, its annual report on Form 10-K for the year ended December 31st, 2021, its quarterly reports on Form 10-Q and its other SEC filings. Although forward-looking statements help to provide complete information about future prospects, listeners should keep in mind that forward-looking statements are based solely on the information available to management as of today. The company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after this call.

With that, I'm pleased to turn the call over to Dr. Gagliano.

Nancy Gagliano

Good evening. Thank you, Scott and thank you, everyone for joining the call today. OraSure once again delivered record revenue this quarter. Perhaps more importantly, we made substantial progress on our InteliSwab manufacturing scale-up and continue to improve the efficiency of our process. This positions us well for increased InteliSwab revenue throughout the remainder of the year. From a demand perspective, we continue to anticipate robust government demand through the end of the calendar year. And we are working to expand our commercial footprint for the test as well.